 |
InterPro: IPR014347 Tautomerase
Protein matches
|
UniProtKB Matches: 1484 proteins |
|
Accession
|
IPR014347 Tautomerase |
Secondary
|
IPR001398
|
Type
|
Domain |
Signatures
|
|
InterPro Relationships
|
|
Children
|
IPR001398 Macrophage migration inhibitory factor
IPR004220 5-carboxymethyl-2-hydroxymuconate isomerase
IPR015017 Protein of unknown function DUF1904
|
|
Found in
|
IPR004370 4-oxalocrotonate tautomerase
IPR018191 4-oxalocrotonate tautomerase, subgroup
|
|
Contains
|
IPR019829 Macrophage migration inhibitory factor, conserved site
|
|
InterPro annotation
|
|
Entry Details in BioMart
|
Abstract
|
Tautomerase superfamily members have a (beta-alpha-beta)2 structure in two layers, and use a similar mechanism of action involving an amino-terminal proline as a general base in a ket-enol tautomerisation reaction [1]. Members of this superfamily include macrophage migration inhibitory factor (MIF) and related proteins such as D-dopachrome tautomerase; 4-oxalocronoate tautomerase and related enzymes such as trans-3-chloroacrylic acid dehalogenase; and
5-carboxymethyl-2-hydroxymuconate isomerase (CHMI).
Macrophage migration inhibitory factor (MIF) is a key regulatory cytokine within innate and adaptive immune responses, capable of promoting and modulating the magnitude of the response [2]. MIF is released from T-cells and macrophages, and it can regulate cytokine secretion and the expression of receptors involved in the immune response. MIF has been linked to various inflammatory diseases, such as rheumatoid arthritis and atherosclerosis [3].
4-Oxalocrotonate tautomerase (4-OT) is a plasmid-encoded enzyme that catalyzes the isomerisation of beta,gamma-unsaturated enones to their alpha,beta-isomers. This enzyme is part of the plasmid-encoded catechol meta-fission pathway, which enables the bacteria to use various aromatic hydrocarbons as their sole sources of carbon and energy [4].
5-carboxymethyl-2-hydroxymuconate isomerase (CHMI) is a trimeric enzyme involved in the homoprotocatechuate pathway in Escherichia coli [5]. This enzyme catalyses the isomerisation of 5-carboxymethyl-2-hydroxymuconate (CHM) to 5-carboxymethyl-2-oxo-3-hexene-1,6-dioate (COHED).
|
Structural links
|
|
Publications
|
|
1.
|
Almrud JJ, Kern AD, Wang SC, Czerwinski RM, Johnson WH Jr, Murzin AG, Hackert ML, Whitman CP.
The crystal structure of YdcE, a 4-oxalocrotonate tautomerase homologue from Escherichia coli, confirms the structural basis for oligomer diversity.
Biochemistry 41 12010-24 2002
[PubMed: 12356301]
http://dx.doi.org/10.1021/bi020271h
|
|
2.
|
Donn RP, Ray DW.
Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule.
J. Endocrinol. 182 1-9 2004
[PubMed: 15225126]
http://dx.doi.org/10.1677/joe.0.1820001
|
|
3.
|
Morand EF, Leech M, Bernhagen J.
MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis.
5 399-410 2006
[PubMed: 16628200]
http://dx.doi.org/10.1038/nrd2029
|
|
4.
|
Whitman CP.
The 4-oxalocrotonate tautomerase family of enzymes: how nature makes new enzymes using a beta-alpha-beta structural motif.
Arch. Biochem. Biophys. 402 1-13 2002
[PubMed: 12051677]
http://dx.doi.org/10.1016/S0003-9861(02)00052-8
|
|
5.
|
Subramanya HS, Roper DI, Dauter Z, Dodson EJ, Davies GJ, Wilson KS, Wigley DB.
Enzymatic ketonization of 2-hydroxymuconate: specificity and mechanism investigated by the crystal structures of two isomerases.
Biochemistry 35 792-802 1996
[PubMed: 8547259]
http://dx.doi.org/10.1021/bi951732k
|
Additional Reading
|
|
Suzuki M, Takamura Y, Maeno M, Tochinai S, Iyaguchi D, Tanaka I, Nishihira J, Ishibashi T.
Xenopus laevis macrophage migration inhibitory factor is essential for axis formation and neural development.
J. Biol. Chem. 279 2004 21406-14
[PubMed: 15024012]
http://dx.doi.org/10.1074/jbc.M311416200
|
|
Golubkov PA, Johnson WH Jr, Czerwinski RM, Person MD, Wang SC, Whitman CP, Hackert ML.
Inactivation of the phenylpyruvate tautomerase activity of macrophage migration inhibitory factor by 2-oxo-4-phenyl-3-butynoate.
Bioorg. Chem. 34 2006 183-99
[PubMed: 16780921]
http://dx.doi.org/10.1016/j.bioorg.2006.05.001
|
|
Almrud JJ, Poelarends GJ, Johnson WH Jr, Serrano H, Hackert ML, Whitman CP.
Crystal structures of the wild-type, P1A mutant, and inactivated malonate semialdehyde decarboxylase: a structural basis for the decarboxylase and hydratase activities.
Biochemistry 44 2005 14818-27
[PubMed: 16274229]
http://dx.doi.org/10.1021/bi051383m
|
|
Crichlow GV, Cheng KF, Dabideen D, Ochani M, Aljabari B, Pavlov VA, Miller EJ, Lolis E, Al-Abed Y.
Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor.
J. Biol. Chem. 282 2007 23089-95
[PubMed: 17526494]
http://dx.doi.org/10.1074/jbc.M701825200
|
|
Winner M, Meier J, Zierow S, Rendon BE, Crichlow GV, Riggs R, Bucala R, Leng L, Smith N, Lolis E, Trent JO, Mitchell RA.
A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells.
Cancer Res. 68 2008 7253-7
[PubMed: 18794110]
http://dx.doi.org/10.1158/0008-5472.CAN-07-6227
|
|
|
InterPro 24.0
|